Few areas in biology are evolving as rapidly as microbiome characterization. Research efforts in this field have dramatically re-positioned microbiology from the periphery to the center of endeavors in developing translational medicine.  Its impact on physiology and, more importantly, the transformation of knowledge into medical applications, have directed the microbiome field down two paths: removing noxious components and harvesting beneficial components of the microbiota.  By expressing factors within the oral cavity and gastrointestinal tract that selectively reduce disease-causing microbial species or secrete beneficial effectors to prevent disease, Intrexon’s proprietary synthetic biology platform holds the potential to develop novel approaches to both. 

Learn more in the ActoBiotics™ white paper.